Cardiol Therapeutics is a clinical stage drug development company with focused on the development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. They are pioneering the use of organic chemistry to produce cannabidiol without ever touching the plant. This patented formulation, called CardiolRx, extends the shelf life of the drug from 90 days to over two years and is being produced at scale in a cGMP lab. Cardiol is currently conducting Phase 2 clinical trials for two indications: Acute Myocaridtis and Recurrent Pericarditis, both of which offer a billion dollar opportunity for which the company is expecting to receive Orphan Drug status. They are also developing a subcutaneous treatment for heart failure which represents a $20B market opportunity. Cardiol’s advisors and trial partners include a who’s who in the industry with leading cardiac physicians from Mayo Clinic, Cleveland Clinic, Brigham and Women’s Hospital, Tel Aviv Medical Center and many others.